Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - alprazolam, quantity: 2 mg - tablet, uncoated - excipient ingredients: sodium benzoate; docusate sodium; maize starch; magnesium stearate; colloidal anhydrous silica; sodium starch glycollate; povidone; microcrystalline cellulose; lactose - anxiety: the short-term symptomatic treatment of anxiety including treatment of anxious patients with some symptoms of depression, and panic disorder: the treatment of panic disorder with or without some phobic avoidance, and for blocking or attenuation of panic attacks and phobias in patients who have agoraphobia with panic attacks.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - alprazolam, quantity: 1 mg - tablet, uncoated - excipient ingredients: indigo carmine; docusate sodium; sodium benzoate; lactose; sodium starch glycollate; povidone; magnesium stearate; maize starch; colloidal anhydrous silica; microcrystalline cellulose - anxiety: the short-term symptomatic treatment of anxiety including treatment of anxious patients with some symptoms of depression, and panic disorder: the treatment of panic disorder with or without some phobic avoidance, and for blocking or attenuation of panic attacks and phobias in patients who have agoraphobia with panic attacks.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - alprazolam, quantity: 0.5 mg - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; maize starch; lactose; povidone; sodium benzoate; magnesium stearate; microcrystalline cellulose; docusate sodium; sodium starch glycollate; colour - anxiety: the short-term symptomatic treatment of anxiety including treatment of anxious patients with some symptoms of depression, and panic disorder: the treatment of panic disorder with or without some phobic avoidance, and for blocking or attenuation of panic attacks and phobias in patients who have agoraphobia with panic attacks.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - alprazolam -

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

شركة أدوية الحكمة - hikma pharmaceuticals - pancuronium bromide 2 mg/ml - 2 mg/ml

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - alprazolam, quantity: 1 mg - tablet, uncoated - excipient ingredients: maize starch; povidone; sodium benzoate; sodium starch glycollate; indigo carmine; microcrystalline cellulose; docusate sodium; magnesium stearate; colloidal anhydrous silica; lactose - anxiety: the short-term symptomatic treatment of anxiety including treatment of anxious patients with some symptoms of depression, and panic disorder: the treatment of panic disorder with or without some phobic avoidance, and for blocking or attenuation of panic attacks and phobias in patients who have agoraphobia with panic attacks.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - alprazolam, quantity: 0.5 mg - tablet, uncoated - excipient ingredients: magnesium stearate; colloidal anhydrous silica; lactose; sodium starch glycollate; microcrystalline cellulose; povidone; sodium benzoate; maize starch; docusate sodium; colour - anxiety: the short-term symptomatic treatment of anxiety including treatment of anxious patients with some symptoms of depression, and panic disorder: the treatment of panic disorder with or without some phobic avoidance, and for blocking or attenuation of panic attacks and phobias in patients who have agoraphobia with panic attacks.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - alprazolam, quantity: 0.25 mg - tablet, uncoated - excipient ingredients: sodium starch glycollate; lactose; docusate sodium; maize starch; microcrystalline cellulose; magnesium stearate; povidone; colloidal anhydrous silica; sodium benzoate - anxiety: the short-term symptomatic treatment of anxiety including treatment of anxious patients with some symptoms of depression, and panic disorder: the treatment of panic disorder with or without some phobic avoidance, and for blocking or attenuation of panic attacks and phobias in patients who have agoraphobia with panic attacks.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - alprazolam, quantity: 0.25 mg - tablet, uncoated - excipient ingredients: lactose; maize starch; povidone; sodium starch glycollate; colloidal anhydrous silica; docusate sodium; microcrystalline cellulose; magnesium stearate; sodium benzoate - anxiety: the short-term symptomatic treatment of anxiety including treatment of anxious patients with some symptoms of depression, and panic disorder: the treatment of panic disorder with or without some phobic avoidance, and for blocking or attenuation of panic attacks and phobias in patients who have agoraphobia with panic attacks.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

white heron pharmaceutical sdn. bhd. - acorus calamus; ganoderma lucidum; radix rehmanniae glutinosa; radix panax quinquefolium l. (american wild ginseng); radix panax ginseng.; radix paeonia lactiflora; radix codonopsis pilosulae; radix acanthopanacis senticosi; ginkgo biloba leaf extract; fructus schisandra chinensis -